The global viral vector and plasmid DNA manufacturing market is anticipated to reach USD 19.5 billion by 2030 and it is projected to grow at a CAGR of 20.2% from 2024 - 2030. With the increasing demand for plasmid DNA and viral vectors for gene therapy, industry leaders have launched new technologies to boost plasmid DNA manufacturing. For instance, in April 2018, GE Healthcare Life Sciences introduced KUBio BSL 2, a prefabricated, modular bioprocessing facility for the production of oncolytic viruses, cell and gene treatments, and immunizations based on viral vectors. ![Global Viral Vector and Plasmid DNA Manufacturing Market]( "Global Viral Vector and Plasmid DNA Manufacturing Market")
With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.
Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.
Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.
With the increase in investments in cell and gene therapy research space, there is unprecedented demand for viral vectors in the market. Owing to this, various organizations are providing funds to accelerate developments in the manufacturing processes for these vectors. For instance, in September 2019, Next Generation Manufacturing Canada provided USD 1.89 million to a consortium led by iVexSol Canada. This fund was provided for the development of an advanced manufacturing process for lentiviral vectors. 2iVexSol Canada is a vector manufacturing company that has collaborated with several companies to develop an advanced LVV manufacturing platform.
Moreover, the major companies operating in this market, such as Thermo Fisher Scientific, QIAGEN NV, Agilent Technologies, Takara Bio, Inc., and Oxford Biomedica, are focusing on developing new gene delivery platforms. These companies are making huge investments to scale up the production of biological gene delivery systems to meet the increasing market demand. For instance, in May 2020, Takara Bio, Inc. completed the Center for Gene and Cell Therapy Processing II (CGCPII) construction in Shiga, Japan. This center is an addition to its GMP viral vector production facility. Similarly, in May 2020, Thermo Fisher Scientific also invested USD 180 million to scale up its viral vector manufacturing capacity twofold. Such increasing initiatives are anticipated to propel market growth in the forecast period.
Furthermore, large-scale production of viral vectors is facing challenges in upstream and downstream processing. In upstream processes, the method used for viral vector production is one of the major hurdles for manufacturers. Reproduction of adherent cell cultures at a large scale is a key concern that needs to be addressed. Thus, researchers are trying to grow these cells using large bioreactors. In addition, there is a need for a better understanding of the purity of these vectors in downstream processing.
Viral Vector And Plasmid DNA Manufacturing Market Report Highlights
- Based on the vector type, the adeno-associated virus (AAV) segment dominated the market with a 20% revenue share in 2023 due to high demand, and their usage in clinical trials is growing
- Based on the workflow, the downstream processing segment led the market in 2023 with the largest revenue share in workflow segment due to advancements in downstream processing technologies and the adoption of single-use systems
- Based on the application, the vaccinology segment dominated the application segment in 2023 with the largest revenue share, and cell therapy is expected to grow at fastest CAGR during the forecast period
- Based on the end-use, the research institutes segment dominated the market with the largest revenue share in 2023. On the other hand, the pharmaceutical and biopharmaceutical companies are expected to grow at a fastest CAGR over the forecast period
- In terms of disease, the cancer segment dominated the market with the largest revenue share in 2023 and it is anticipated to grow at fastest CAGR during the forecast period
- North America dominated the market owing to factors such as the significant burden of cancer, and infectious diseases, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Vector type
1.2.2. Workflow
1.2.3. Application
1.2.4. End-use
1.2.5. Disease
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Vector type
1.2.2. Workflow
1.2.3. Application
1.2.4. End-use
1.2.5. Disease
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Viral Vectors And Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
3.2.1.2. Technological Advancements in Manufacturing Vectors
3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
3.2.2. Market restraint analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Robust Pipeline for Gene Therapies and Viral Vector Vaccines
3.2.1.2. Technological Advancements in Manufacturing Vectors
3.2.1.3. Highly Competitive Market and Various Strategies Undertaken by Market Entities
3.2.2. Market restraint analysis
3.2.2.1. Regulatory, Scientific, And Ethical Challenges Associated With Gene Therapy And Viral Vectors
3.3. Viral Vectors And Plasmid DNA Manufacturing Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Viral Vectors And Plasmid DNA Manufacturing Market: Vector Type Estimates & Trend Analysis
4.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Vector Type Outlook
4.2. Adeno-associated virus (AAV)
4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.3. Lentivirus
4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.4. Adenovirus
4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.5. Retrovirus
4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.6. Plasmids
4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.2. Adeno-associated virus (AAV)
4.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.3. Lentivirus
4.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.4. Adenovirus
4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.5. Retrovirus
4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.6. Plasmids
4.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)
4.7. Others
4.7.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 5. Viral Vectors And Plasmid DNA Manufacturing Market: Workflow Estimates & Trend Analysis
5.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Workflow Outlook
5.2. Upstream Manufacturing
5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.2.2. Vector Amplification & Expansion
5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.2.3. Vector Recovery/Harvesting
5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.3. Downstream Manufacturing
5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.3.2. Purification
5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.3.3. Fill Finish diagnostic instruments
5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.2. Upstream Manufacturing
5.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.2.2. Vector Amplification & Expansion
5.2.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.2.3. Vector Recovery/Harvesting
5.2.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.3. Downstream Manufacturing
5.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.3.2. Purification
5.3.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
5.3.3. Fill Finish diagnostic instruments
5.3.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 6. Viral Vectors And Plasmid DNA Manufacturing Market: Application Estimates & Trend Analysis
6.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Application Outlook
6.2. Gene Therapy
6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.3. Cell Therapy
6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.4. Vaccinology
6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.5. Research Applications
6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.2. Gene Therapy
6.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.3. Cell Therapy
6.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.4. Vaccinology
6.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
6.5. Research Applications
6.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 7. Viral Vectors And Plasmid DNA Manufacturing Market: End-use Estimates & Trend Analysis
7.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by End-use Outlook
7.2. Pharmaceutical and Biopharmaceutical Companies
7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
7.3. Research Institutes
7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
7.2. Pharmaceutical and Biopharmaceutical Companies
7.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
7.3. Research Institutes
7.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 8. Viral Vectors And Plasmid DNA Manufacturing Market: Disease Estimates & Trend Analysis
8.1. Global Viral Vectors And Plasmid DNA Manufacturing Market by Disease Outlook
8.2. Cancer
8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.3. Genetic Disorders
8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.4. Infectious Diseases
8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.5. Other
8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.2. Cancer
8.2.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.3. Genetic Disorders
8.3.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.4. Infectious Diseases
8.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
8.5. Other
8.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
Chapter 9. Viral Vectors And Plasmid DNA Manufacturing Market: Regional Estimates & Trend Analysis
9.1. Regional Market Share Analysis, 2023 & 2030
9.2. North America
9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
9.2.2. U.S.
9.2.2.1. Key country dynamics
9.2.2.2. Regulatory framework
9.2.2.3. Competitive scenario
9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
9.2.2.5. Target disease prevalence
9.2.3. Canada
9.2.3.1. Key country dynamics
9.2.3.2. Regulatory framework
9.2.3.3. Competitive scenario
9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
9.2.3.5. Target disease prevalence
9.3. Europe
9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
9.3.2. UK
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Germany
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
9.3.3.5. Target disease prevalence
9.3.4. France
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework
9.3.4.3. Competitive scenario
9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
9.3.4.5. Target disease prevalence
9.3.5. Italy
9.3.5.1. Key country dynamics
9.3.5.2. Regulatory framework
9.3.5.3. Competitive scenario
9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
9.3.5.5. Target disease prevalence
9.3.6. Spain
9.3.6.1. Key country dynamics
9.3.6.2. Regulatory framework
9.3.6.3. Competitive scenario
9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
9.3.6.5. Target disease prevalence
9.3.7. Norway
9.3.7.1. Key country dynamics
9.3.7.2. Regulatory framework
9.3.7.3. Competitive scenario
9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
9.3.7.5. Target disease prevalence
9.3.8. Sweden
9.3.8.1. Key country dynamics
9.3.8.2. Regulatory framework
9.3.8.3. Competitive scenario
9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
9.3.8.5. Target disease prevalence
9.3.9. Denmark
9.3.9.1. Key country dynamics
9.3.9.2. Regulatory framework
9.3.9.3. Competitive scenario
9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
9.3.9.5. Target disease prevalence
9.4. Asia-Pacific
9.4.1. Asia-Pacific market estimates and forecasts 2018 to 2030, (USD Million)
9.4.2. Japan
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. China
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. India
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Australia
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. South Korea
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Thailand
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
9.4.7.5. Target disease prevalence
9.5. Latin America
9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
9.5.2. Brazil
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. Mexico
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Argentina
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
9.5.4.5. Target disease prevalence
9.6. MEA
9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
9.6.2. South Africa
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
9.6.2.5. Target disease prevalence
9.6.3. Saudi Arabia
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework
9.6.3.3. Competitive scenario
9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
9.6.3.5. Target disease prevalence
9.6.4. UAE
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework
9.6.4.3. Competitive scenario
9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
9.6.4.5. Target disease prevalence
9.6.5. Kuwait
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework
9.6.5.3. Competitive scenario
9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
9.6.5.5. Target disease prevalence
9.2. North America
9.2.1. North America market estimates and forecasts 2018 to 2030, (USD Million)
9.2.2. U.S.
9.2.2.1. Key country dynamics
9.2.2.2. Regulatory framework
9.2.2.3. Competitive scenario
9.2.2.4. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
9.2.2.5. Target disease prevalence
9.2.3. Canada
9.2.3.1. Key country dynamics
9.2.3.2. Regulatory framework
9.2.3.3. Competitive scenario
9.2.3.4. Canada market estimates and forecasts 2018 to 2030, (USD Million)
9.2.3.5. Target disease prevalence
9.3. Europe
9.3.1. Europe market estimates and forecasts 2018 to 2030, (USD Million)
9.3.2. UK
9.3.2.1. Key country dynamics
9.3.2.2. Regulatory framework
9.3.2.3. Competitive scenario
9.3.2.4. UK market estimates and forecasts 2018 to 2030, (USD Million)
9.3.2.5. Target disease prevalence
9.3.3. Germany
9.3.3.1. Key country dynamics
9.3.3.2. Regulatory framework
9.3.3.3. Competitive scenario
9.3.3.4. Germany market estimates and forecasts 2018 to 2030, (USD Million)
9.3.3.5. Target disease prevalence
9.3.4. France
9.3.4.1. Key country dynamics
9.3.4.2. Regulatory framework
9.3.4.3. Competitive scenario
9.3.4.4. France market estimates and forecasts 2018 to 2030, (USD Million)
9.3.4.5. Target disease prevalence
9.3.5. Italy
9.3.5.1. Key country dynamics
9.3.5.2. Regulatory framework
9.3.5.3. Competitive scenario
9.3.5.4. Italy market estimates and forecasts 2018 to 2030, (USD Million)
9.3.5.5. Target disease prevalence
9.3.6. Spain
9.3.6.1. Key country dynamics
9.3.6.2. Regulatory framework
9.3.6.3. Competitive scenario
9.3.6.4. Spain market estimates and forecasts 2018 to 2030, (USD Million)
9.3.6.5. Target disease prevalence
9.3.7. Norway
9.3.7.1. Key country dynamics
9.3.7.2. Regulatory framework
9.3.7.3. Competitive scenario
9.3.7.4. Norway market estimates and forecasts 2018 to 2030, (USD Million)
9.3.7.5. Target disease prevalence
9.3.8. Sweden
9.3.8.1. Key country dynamics
9.3.8.2. Regulatory framework
9.3.8.3. Competitive scenario
9.3.8.4. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
9.3.8.5. Target disease prevalence
9.3.9. Denmark
9.3.9.1. Key country dynamics
9.3.9.2. Regulatory framework
9.3.9.3. Competitive scenario
9.3.9.4. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
9.3.9.5. Target disease prevalence
9.4. Asia-Pacific
9.4.1. Asia-Pacific market estimates and forecasts 2018 to 2030, (USD Million)
9.4.2. Japan
9.4.2.1. Key country dynamics
9.4.2.2. Regulatory framework
9.4.2.3. Competitive scenario
9.4.2.4. Japan market estimates and forecasts 2018 to 2030, (USD Million)
9.4.2.5. Target disease prevalence
9.4.3. China
9.4.3.1. Key country dynamics
9.4.3.2. Regulatory framework
9.4.3.3. Competitive scenario
9.4.3.4. China market estimates and forecasts 2018 to 2030, (USD Million)
9.4.3.5. Target disease prevalence
9.4.4. India
9.4.4.1. Key country dynamics
9.4.4.2. Regulatory framework
9.4.4.3. Competitive scenario
9.4.4.4. India market estimates and forecasts 2018 to 2030, (USD Million)
9.4.4.5. Target disease prevalence
9.4.5. Australia
9.4.5.1. Key country dynamics
9.4.5.2. Regulatory framework
9.4.5.3. Competitive scenario
9.4.5.4. Australia market estimates and forecasts 2018 to 2030, (USD Million)
9.4.5.5. Target disease prevalence
9.4.6. South Korea
9.4.6.1. Key country dynamics
9.4.6.2. Regulatory framework
9.4.6.3. Competitive scenario
9.4.6.4. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
9.4.6.5. Target disease prevalence
9.4.7. Thailand
9.4.7.1. Key country dynamics
9.4.7.2. Regulatory framework
9.4.7.3. Competitive scenario
9.4.7.4. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
9.4.7.5. Target disease prevalence
9.5. Latin America
9.5.1. Latin America market estimates and forecasts 2018 to 2030, (USD Million)
9.5.2. Brazil
9.5.2.1. Key country dynamics
9.5.2.2. Regulatory framework
9.5.2.3. Competitive scenario
9.5.2.4. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
9.5.2.5. Target disease prevalence
9.5.3. Mexico
9.5.3.1. Key country dynamics
9.5.3.2. Regulatory framework
9.5.3.3. Competitive scenario
9.5.3.4. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
9.5.3.5. Target disease prevalence
9.5.4. Argentina
9.5.4.1. Key country dynamics
9.5.4.2. Regulatory framework
9.5.4.3. Competitive scenario
9.5.4.4. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
9.5.4.5. Target disease prevalence
9.6. MEA
9.6.1. MEA market estimates and forecasts 2018 to 2030, (USD Million)
9.6.2. South Africa
9.6.2.1. Key country dynamics
9.6.2.2. Regulatory framework
9.6.2.3. Competitive scenario
9.6.2.4. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
9.6.2.5. Target disease prevalence
9.6.3. Saudi Arabia
9.6.3.1. Key country dynamics
9.6.3.2. Regulatory framework
9.6.3.3. Competitive scenario
9.6.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
9.6.3.5. Target disease prevalence
9.6.4. UAE
9.6.4.1. Key country dynamics
9.6.4.2. Regulatory framework
9.6.4.3. Competitive scenario
9.6.4.4. UAE market estimates and forecasts 2018 to 2030, (USD Million)
9.6.4.5. Target disease prevalence
9.6.5. Kuwait
9.6.5.1. Key country dynamics
9.6.5.2. Regulatory framework
9.6.5.3. Competitive scenario
9.6.5.4. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
9.6.5.5. Target disease prevalence
Chapter 10. Competitive Landscape
10.1. Company Categorization
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2023
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Lonza
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. FUJIFILM Diosynth Biotechnologies
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Thermo Fisher Scientific
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Cobra Biologics
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Catalent Inc.
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Wuxi Biologics
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Takara Bio Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Waisman Biomanufacturing
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Genezen laboratories
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
10.4.11. Batavia Biosciences
10.4.11.1. Company overview
10.4.11.2. Financial performance
10.4.11.3. Product benchmarking
10.4.11.4. Strategic initiatives
10.4.12. Miltenyi Biotec GmbH
10.4.12.1. Company overview
10.4.12.2. Financial performance
10.4.12.3. Product benchmarking
10.4.12.4. Strategic initiatives
10.4.13. SIRION Biotech GmbH
10.4.13.1. Company overview
10.4.13.2. Financial performance
10.4.13.3. Product benchmarking
10.4.13.4. Strategic initiatives
10.4.14. Virovek Incorporation
10.4.14.1. Company overview
10.4.14.2. Financial performance
10.4.14.3. Product benchmarking
10.4.14.4. Strategic initiatives
10.4.15. BioNTech IMFS GmbH
10.4.15.1. Company overview
10.4.15.2. Financial performance
10.4.15.3. Product benchmarking
10.4.15.4. Strategic initiatives
10.4.16. Audentes Therapeutics
10.4.16.1. Company overview
10.4.16.2. Financial performance
10.4.16.3. Product benchmarking
10.4.16.4. Strategic initiatives
10.4.17. BioMarin Pharmaceutical
10.4.17.1. Company overview
10.4.17.2. Financial performance
10.4.17.3. Product benchmarking
10.4.17.4. Strategic initiatives
10.4.18. RegenxBio, Inc.
10.4.18.1. Company overview
10.4.18.2. Financial performance
10.4.18.3. Product benchmarking
10.4.18.4. Strategic initiatives
10.2. Strategy Mapping
10.3. Company Market Position Analysis, 2023
10.4. Company Profiles/Listing
10.4.1. Merck KGaA
10.4.1.1. Company overview
10.4.1.2. Financial performance
10.4.1.3. Product benchmarking
10.4.1.4. Strategic initiatives
10.4.2. Lonza
10.4.2.1. Company overview
10.4.2.2. Financial performance
10.4.2.3. Product benchmarking
10.4.2.4. Strategic initiatives
10.4.3. FUJIFILM Diosynth Biotechnologies
10.4.3.1. Company overview
10.4.3.2. Financial performance
10.4.3.3. Product benchmarking
10.4.3.4. Strategic initiatives
10.4.4. Thermo Fisher Scientific
10.4.4.1. Company overview
10.4.4.2. Financial performance
10.4.4.3. Product benchmarking
10.4.4.4. Strategic initiatives
10.4.5. Cobra Biologics
10.4.5.1. Company overview
10.4.5.2. Financial performance
10.4.5.3. Product benchmarking
10.4.5.4. Strategic initiatives
10.4.6. Catalent Inc.
10.4.6.1. Company overview
10.4.6.2. Financial performance
10.4.6.3. Product benchmarking
10.4.6.4. Strategic initiatives
10.4.7. Wuxi Biologics
10.4.7.1. Company overview
10.4.7.2. Financial performance
10.4.7.3. Product benchmarking
10.4.7.4. Strategic initiatives
10.4.8. Takara Bio Inc.
10.4.8.1. Company overview
10.4.8.2. Financial performance
10.4.8.3. Product benchmarking
10.4.8.4. Strategic initiatives
10.4.9. Waisman Biomanufacturing
10.4.9.1. Company overview
10.4.9.2. Financial performance
10.4.9.3. Product benchmarking
10.4.9.4. Strategic initiatives
10.4.10. Genezen laboratories
10.4.10.1. Company overview
10.4.10.2. Financial performance
10.4.10.3. Product benchmarking
10.4.10.4. Strategic initiatives
10.4.11. Batavia Biosciences
10.4.11.1. Company overview
10.4.11.2. Financial performance
10.4.11.3. Product benchmarking
10.4.11.4. Strategic initiatives
10.4.12. Miltenyi Biotec GmbH
10.4.12.1. Company overview
10.4.12.2. Financial performance
10.4.12.3. Product benchmarking
10.4.12.4. Strategic initiatives
10.4.13. SIRION Biotech GmbH
10.4.13.1. Company overview
10.4.13.2. Financial performance
10.4.13.3. Product benchmarking
10.4.13.4. Strategic initiatives
10.4.14. Virovek Incorporation
10.4.14.1. Company overview
10.4.14.2. Financial performance
10.4.14.3. Product benchmarking
10.4.14.4. Strategic initiatives
10.4.15. BioNTech IMFS GmbH
10.4.15.1. Company overview
10.4.15.2. Financial performance
10.4.15.3. Product benchmarking
10.4.15.4. Strategic initiatives
10.4.16. Audentes Therapeutics
10.4.16.1. Company overview
10.4.16.2. Financial performance
10.4.16.3. Product benchmarking
10.4.16.4. Strategic initiatives
10.4.17. BioMarin Pharmaceutical
10.4.17.1. Company overview
10.4.17.2. Financial performance
10.4.17.3. Product benchmarking
10.4.17.4. Strategic initiatives
10.4.18. RegenxBio, Inc.
10.4.18.1. Company overview
10.4.18.2. Financial performance
10.4.18.3. Product benchmarking
10.4.18.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 18 Europe viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 19 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 20 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 21 Europe viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 22 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 23 Europe viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 24 UK viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 25 UK viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 26 UK viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 27 UK viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 28 UK viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 29 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 30 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 31 Germany viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 32 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 33 Germany viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 34 France viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 35 France viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 36 France viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 37 France viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 38 France viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 39 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 40 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 41 Spain viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 42 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 43 Spain viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 44 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 45 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 46 Italy viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 47 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 48 Italy viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 49 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 50 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 51 Denmark viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 52 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 53 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 54 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 55 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 56 Sweden viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 57 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 58 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 59 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 60 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 61 Norway viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 62 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 63 Norway viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 64 Asia-Pacific viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 65 Asia-Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 66 Asia-Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 67 Asia-Pacific viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 68 Asia-Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 69 Asia-Pacific viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 70 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 71 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 72 Japan viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 73 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 74 Japan viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 75 China viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 76 China viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 77 China viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 78 China viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 79 China viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 80 India viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 81 India viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 82 India viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 83 India viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 84 India viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 85 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 86 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 87 South Korea viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 88 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 89 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 90 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 91 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 92 Australia viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 93 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 94 Australia viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 95 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 96 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 97 Thailand viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 98 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 99 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 100 Latin America viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 101 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 102 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 103 Latin America viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 104 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 105 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 106 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 107 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 108 Brazil viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 109 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 110 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 111 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 112 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 113 Mexico viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 114 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 115 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 2 North America viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 3 North America viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 4 North America viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 5 North America viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 6 North America viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 7 North America viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 8 U.S. viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 9 U.S. viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 10 U.S. viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 11 U.S. viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 12 U.S. viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 13 Canada viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 14 Canada viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 15 Canada viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 16 Canada viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 17 Canada viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 18 Europe viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 19 Europe viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 20 Europe viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 21 Europe viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 22 Europe viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 23 Europe viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 24 UK viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 25 UK viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 26 UK viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 27 UK viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 28 UK viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 29 Germany viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 30 Germany viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 31 Germany viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 32 Germany viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 33 Germany viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 34 France viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 35 France viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 36 France viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 37 France viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 38 France viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 39 Spain viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 40 Spain viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 41 Spain viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 42 Spain viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 43 Spain viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 44 Italy viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 45 Italy viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 46 Italy viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 47 Italy viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 48 Italy viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 49 Denmark viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 50 Denmark viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 51 Denmark viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 52 Denmark viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 53 Denmark viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 54 Sweden viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 55 Sweden viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 56 Sweden viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 57 Sweden viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 58 Sweden viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 59 Norway viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 60 Norway viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 61 Norway viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 62 Norway viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 63 Norway viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 64 Asia-Pacific viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 65 Asia-Pacific viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 66 Asia-Pacific viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 67 Asia-Pacific viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 68 Asia-Pacific viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 69 Asia-Pacific viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 70 Japan viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 71 Japan viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 72 Japan viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 73 Japan viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 74 Japan viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 75 China viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 76 China viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 77 China viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 78 China viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 79 China viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 80 India viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 81 India viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 82 India viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 83 India viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 84 India viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 85 South Korea viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 86 South Korea viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 87 South Korea viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 88 South Korea viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 89 South Korea viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 90 Australia viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 91 Australia viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 92 Australia viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 93 Australia viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 94 Australia viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 95 Thailand viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 96 Thailand viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 97 Thailand viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 98 Thailand viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 99 Thailand viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 100 Latin America viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 101 Latin America viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 102 Latin America viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 103 Latin America viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 104 Latin America viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 105 Latin America viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 106 Brazil viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 107 Brazil viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 108 Brazil viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 109 Brazil viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 110 Brazil viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 111 Mexico viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 112 Mexico viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 113 Mexico viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 114 Mexico viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 115 Mexico viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 116 Argentina viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 117 Argentina viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 118 Argentina viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 119 Argentina viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 120 Argentina viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 121 Middle East and Africa viral vector and plasmid DNA manufacturing market, by region, 2018-2030 (USD Million)
Table 122 Middle East and Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 123 Middle East and Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 124 Middle East and Africa viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 125 Middle East and Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 126 Middle East and Africa viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 127 South Africa viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 128 South Africa viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 129 South Africa viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 130 South Africa viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 131 South Africa viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 132 Saudi Arabia viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 133 Saudi Arabia viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 134 Saudi Arabia viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 135 Saudi Arabia viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 136 Saudi Arabia viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 137 UAE viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 138 UAE viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 139 UAE viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 140 UAE viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 141 UAE viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
Table 142 Kuwait viral vector and plasmid DNA manufacturing market, by vector type, 2018-2030 (USD Million)
Table 143 Kuwait viral vector and plasmid DNA manufacturing market, by workflow, 2018-2030 (USD Million)
Table 144 Kuwait viral vector and plasmid DNA manufacturing market, by application, 2018-2030 (USD Million)
Table 145 Kuwait viral vector and plasmid DNA manufacturing market, by end-use, 2018-2030 (USD Million)
Table 146 Kuwait viral vector and plasmid DNA manufacturing market, by disease, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Viral vector and plasmid DNA manufacturing market driver impact
Fig. 15 Viral vector and plasmid DNA manufacturing market restraint impact
Fig. 16 Viral vector and plasmid DNA manufacturing market strategic initiatives analysis
Fig. 17 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
Fig. 18 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
Fig. 19 Adenovirus market estimates and forecast, 2018-2030
Fig. 20 Retrovirus market estimates and forecast, 2018-2030
Fig. 21 Adeno-Associated Virus (AAV)market estimates and forecast, 2018-2030
Fig. 22 Lentivirus market estimates and forecast, 2018-2030
Fig. 23 Plasmids market estimates and forecast, 2018-2030
Fig. 24 Others market estimates and forecast, 2018-2030
Fig. 25 Viral vector and plasmid DNA manufacturing market: Workflow movement Analysis
Fig. 26 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
Fig. 27 Upstream manufacturing market estimates and forecasts, 2018-2030
Fig. 28 Vector amplification & expansion market estimates and forecasts, 2018-2030
Fig. 29 Vector recovery/harvesting market estimates and forecasts, 2018-2030
Fig. 30 Downstream manufacturing market estimates and forecasts, 2018-2030
Fig. 31 Purification market estimates and forecasts, 2018-2030
Fig. 32 Fill finish market estimates and forecasts, 2018-2030
Fig. 33 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
Fig. 34 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
Fig. 35 Antisense & RNAi therapy market estimates and forecasts, 2018-2030
Fig. 36 Gene Therapy market estimates and forecasts, 2018-2030
Fig. 37 Cell Therapy market estimates and forecasts, 2018-2030
Fig. 38 Vaccinology market estimates and forecasts, 2018-2030
Fig. 39 Research Applications market estimates and forecasts, 2018-2030
Fig. 40 Viral vector and plasmid DNA manufacturing market: End-use movement Analysis
Fig. 41 Viral vector and plasmid DNA manufacturing market: End-use outlook and key takeaways
Fig. 42 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2018-2030
Fig. 43 Research institutes market estimates and forecasts, 2018-2030
Fig. 44 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
Fig. 45 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 46 Cancer market estimates and forecasts, 2018-2030
Fig. 47 Genetic disorders market estimates and forecasts, 2018-2030
Fig. 48 Infectious Diseases market estimates and forecasts, 2018-2030
Fig. 49 Others market estimates and forecasts, 2018-2030
Fig. 50 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
Fig. 51 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
Fig. 52 Global viral vector and plasmid DNA manufacturing market share and leading players
Fig. 53 North America, by country
Fig. 54 North America
Fig. 55 North America market estimates and forecasts, 2018-2030
Fig. 56 U.S.
Fig. 57 U.S. market estimates and forecasts, 2018-2030
Fig. 58 Canada
Fig. 59 Canada market estimates and forecasts, 2018-2030
Fig. 60 Europe
Fig. 61 Europe market estimates and forecasts, 2018-2030
Fig. 62 UK
Fig. 63 UK market estimates and forecasts, 2018-2030
Fig. 64 Germany
Fig. 65 Germany market estimates and forecasts, 2018-2030
Fig. 66 France
Fig. 67 France market estimates and forecasts, 2018-2030
Fig. 68 Italy
Fig. 69 Italy market estimates and forecasts, 2018-2030
Fig. 70 Spain
Fig. 71 Spain market estimates and forecasts, 2018-2030
Fig. 72 Denmark
Fig. 73 Denmark market estimates and forecasts, 2018-2030
Fig. 74 Sweden
Fig. 75 Sweden market estimates and forecasts, 2018-2030
Fig. 76 Norway
Fig. 77 Norway market estimates and forecasts, 2018-2030
Fig. 78 Asia-Pacific
Fig. 79 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 80 China
Fig. 81 China market estimates and forecasts, 2018-2030
Fig. 82 Japan
Fig. 83 Japan market estimates and forecasts, 2018-2030
Fig. 84 India
Fig. 85 India market estimates and forecasts, 2018-2030
Fig. 86 Thailand
Fig. 87 Thailand market estimates and forecasts, 2018-2030
Fig. 88 South Korea
Fig. 89 South Korea market estimates and forecasts, 2018-2030
Fig. 90 Australia
Fig. 91 Australia market estimates and forecasts, 2018-2030
Fig. 92 Latin America
Fig. 93 Latin America market estimates and forecasts, 2018-2030
Fig. 94 Brazil
Fig. 95 Brazil market estimates and forecasts, 2018-2030
Fig. 96 Mexico
Fig. 97 Mexico market estimates and forecasts, 2018-2030
Fig. 98 Argentina
Fig. 99 Argentina market estimates and forecasts, 2018-2030
Fig. 100 Middle East and Africa
Fig. 101 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 102 South Africa
Fig. 103 South Africa market estimates and forecasts, 2018-2030
Fig. 104 Saudi Arabia
Fig. 105 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 106 UAE
Fig. 107 UAE market estimates and forecasts, 2018-2030
Fig. 108 Kuwait
Fig. 109 Kuwait market estimates and forecasts, 2018-2030
Fig. 110 Market share of key market players- Viral vector and plasmid DNA manufacturing market
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Viral vector and plasmid DNA manufacturing market: market outlook
Fig. 9 Viral vector and plasmid DNA manufacturing competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Viral vector and plasmid DNA manufacturing market driver impact
Fig. 15 Viral vector and plasmid DNA manufacturing market restraint impact
Fig. 16 Viral vector and plasmid DNA manufacturing market strategic initiatives analysis
Fig. 17 Viral vector and plasmid DNA manufacturing market: Vector type movement analysis
Fig. 18 Viral vector and plasmid DNA manufacturing market: Vector type outlook and key takeaways
Fig. 19 Adenovirus market estimates and forecast, 2018-2030
Fig. 20 Retrovirus market estimates and forecast, 2018-2030
Fig. 21 Adeno-Associated Virus (AAV)market estimates and forecast, 2018-2030
Fig. 22 Lentivirus market estimates and forecast, 2018-2030
Fig. 23 Plasmids market estimates and forecast, 2018-2030
Fig. 24 Others market estimates and forecast, 2018-2030
Fig. 25 Viral vector and plasmid DNA manufacturing market: Workflow movement Analysis
Fig. 26 Viral vector and plasmid DNA manufacturing market: Workflow outlook and key takeaways
Fig. 27 Upstream manufacturing market estimates and forecasts, 2018-2030
Fig. 28 Vector amplification & expansion market estimates and forecasts, 2018-2030
Fig. 29 Vector recovery/harvesting market estimates and forecasts, 2018-2030
Fig. 30 Downstream manufacturing market estimates and forecasts, 2018-2030
Fig. 31 Purification market estimates and forecasts, 2018-2030
Fig. 32 Fill finish market estimates and forecasts, 2018-2030
Fig. 33 Viral vector and plasmid DNA manufacturing market: Application movement Analysis
Fig. 34 Viral vector and plasmid DNA manufacturing market: Application outlook and key takeaways
Fig. 35 Antisense & RNAi therapy market estimates and forecasts, 2018-2030
Fig. 36 Gene Therapy market estimates and forecasts, 2018-2030
Fig. 37 Cell Therapy market estimates and forecasts, 2018-2030
Fig. 38 Vaccinology market estimates and forecasts, 2018-2030
Fig. 39 Research Applications market estimates and forecasts, 2018-2030
Fig. 40 Viral vector and plasmid DNA manufacturing market: End-use movement Analysis
Fig. 41 Viral vector and plasmid DNA manufacturing market: End-use outlook and key takeaways
Fig. 42 Pharmaceutical and biopharmaceutical companies market estimates and forecasts, 2018-2030
Fig. 43 Research institutes market estimates and forecasts, 2018-2030
Fig. 44 Viral vector and plasmid DNA manufacturing market: Disease movement Analysis
Fig. 45 Viral vector and plasmid DNA manufacturing market: Disease outlook and key takeaways
Fig. 46 Cancer market estimates and forecasts, 2018-2030
Fig. 47 Genetic disorders market estimates and forecasts, 2018-2030
Fig. 48 Infectious Diseases market estimates and forecasts, 2018-2030
Fig. 49 Others market estimates and forecasts, 2018-2030
Fig. 50 Global viral vector and plasmid DNA manufacturing market: Regional movement analysis
Fig. 51 Global viral vector and plasmid DNA manufacturing market: Regional outlook and key takeaways
Fig. 52 Global viral vector and plasmid DNA manufacturing market share and leading players
Fig. 53 North America, by country
Fig. 54 North America
Fig. 55 North America market estimates and forecasts, 2018-2030
Fig. 56 U.S.
Fig. 57 U.S. market estimates and forecasts, 2018-2030
Fig. 58 Canada
Fig. 59 Canada market estimates and forecasts, 2018-2030
Fig. 60 Europe
Fig. 61 Europe market estimates and forecasts, 2018-2030
Fig. 62 UK
Fig. 63 UK market estimates and forecasts, 2018-2030
Fig. 64 Germany
Fig. 65 Germany market estimates and forecasts, 2018-2030
Fig. 66 France
Fig. 67 France market estimates and forecasts, 2018-2030
Fig. 68 Italy
Fig. 69 Italy market estimates and forecasts, 2018-2030
Fig. 70 Spain
Fig. 71 Spain market estimates and forecasts, 2018-2030
Fig. 72 Denmark
Fig. 73 Denmark market estimates and forecasts, 2018-2030
Fig. 74 Sweden
Fig. 75 Sweden market estimates and forecasts, 2018-2030
Fig. 76 Norway
Fig. 77 Norway market estimates and forecasts, 2018-2030
Fig. 78 Asia-Pacific
Fig. 79 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 80 China
Fig. 81 China market estimates and forecasts, 2018-2030
Fig. 82 Japan
Fig. 83 Japan market estimates and forecasts, 2018-2030
Fig. 84 India
Fig. 85 India market estimates and forecasts, 2018-2030
Fig. 86 Thailand
Fig. 87 Thailand market estimates and forecasts, 2018-2030
Fig. 88 South Korea
Fig. 89 South Korea market estimates and forecasts, 2018-2030
Fig. 90 Australia
Fig. 91 Australia market estimates and forecasts, 2018-2030
Fig. 92 Latin America
Fig. 93 Latin America market estimates and forecasts, 2018-2030
Fig. 94 Brazil
Fig. 95 Brazil market estimates and forecasts, 2018-2030
Fig. 96 Mexico
Fig. 97 Mexico market estimates and forecasts, 2018-2030
Fig. 98 Argentina
Fig. 99 Argentina market estimates and forecasts, 2018-2030
Fig. 100 Middle East and Africa
Fig. 101 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 102 South Africa
Fig. 103 South Africa market estimates and forecasts, 2018-2030
Fig. 104 Saudi Arabia
Fig. 105 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 106 UAE
Fig. 107 UAE market estimates and forecasts, 2018-2030
Fig. 108 Kuwait
Fig. 109 Kuwait market estimates and forecasts, 2018-2030
Fig. 110 Market share of key market players- Viral vector and plasmid DNA manufacturing market
Companies Mentioned
- Merck KGaA
- Lonza
- FUJIFILM Diosynth Biotechnologies
- Thermo Fisher Scientific
- Cobra Biologics
- Catalent Inc.
- Wuxi Biologics
- Takara Bio Inc.
- Waisman Biomanufacturing
- Genezen Laboratories
- Batavia Biosciences
- Miltenyi Biotec GmBH
- SIRION Biotech GmBH
- Virovek Incorporation
- BioNTech IMFS GmBh
- Audentes Therapeutics
- BioMarin Pharmaceutical
- RegenxBio, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | January 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 5.33 Billion |
| Forecasted Market Value ( USD | $ 19.5 Billion |
| Compound Annual Growth Rate | 20.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
